

POST-TEST

Cases from the Community: Investigators Discuss the Optimal Role of Endocrine-Based and Other Strategies in the Management of HR-Positive Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III INAVO120 trial reported which results with the addition of inavolisib to first-line palbociclib/fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative endocrine-resistant advanced breast cancer?
 - a. No improvement in overall survival (OS)
 - b. Numerical trend toward improved OS
 - c. Statistically significant improvement in OS
2. Recently presented data from the Phase III evERA study reported which efficacy outcome in the intent-to-treat population with giredestrant and everolimus compared to standard endocrine therapy and everolimus for patients with HR-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor?
 - a. A numerical but not statistically significant improvement in progression-free survival (PFS)
 - b. A clinically meaningful and statistically significant improvement in PFS
 - c. A numerical but not statistically significant decrease in PFS
 - d. A clinically meaningful and statistically significant decrease in PFS
3. In the MINDACT study evaluating the utility of the MammaPrint® 70-gene signature test for patients with localized breast cancer, the long-term benefit of adjuvant chemotherapy was maintained in which patient population?
 - a. Premenopausal women
 - b. Postmenopausal women
 - c. Patients older than 50 years
 - d. Patients aged 50 or younger
 - e. All of the above
4. What is the optimal ESR1 mutation testing method for patients with ER-positive breast cancer?
 - a. IHC (immunohistochemistry)
 - b. FISH (fluorescence in situ hybridization)
 - c. Next-generation sequencing (NGS) tissue biopsy
 - d. NGS liquid biopsy
5. Which of the following groups of patients with HR-positive, HER2-negative breast cancer, 1 to 3 positive nodes and a 21-gene Recurrence Score® of 25 or lower derived a benefit in invasive disease-free survival with the addition of chemotherapy to adjuvant endocrine therapy in the RxPONDER trial?
 - a. Premenopausal women only
 - b. Postmenopausal women only
 - c. Both premenopausal and postmenopausal women
 - d. Neither postmenopausal nor premenopausal women